Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Betrixaban in Pediatric Patients
NCT03346083Phase 1Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of betrixaban in venous thromboembolism (VTE) (2 cohorts), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Plasma Concentration-Time Curve From 0 To Infinity and Maximum Observed Plasma Concentration. Started Jul 2018; status: terminated.
02
Drugs
betrixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03346083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346083.